Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-1206 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-1206 monotherapy one time daily up to 35 cycles. |
| Part B: Dose Expansion | EXPERIMENTAL | Participants will be enrolled in different indication specific cohorts. Participants will receive GS-1206 monotherapy at the recommended dose one time daily up to 35 cycles. |
| Name | Type | Description |
|---|---|---|
| GS-1206 | DRUG | Administered Orally |
Key Inclusion Criteria: * All individuals must have a tumor with protocol-specified mutation as determined by local health-authority approved test. * For Part A (including backfill cohorts): Individuals with histologically confirmed advanced or metastatic solid tumors who have progressed following ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-1206 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, with a study evaluating its safety and antitumor activity in adults with solid tumors.
GS-1206 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker GILD. The company is conducting a Phase 1 trial of GS-1206 in adults with solid tumors.
GS-1206 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study is currently recruiting participants to evaluate its safety and antitumor activity in solid tumors.
GS-1206 is being studied in a Phase 1 clinical trial with the identifier NCT07703878. The trial is titled "A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors" and is currently recruiting participants in the United States.
Yes, the Phase 1 clinical trial of GS-1206 is a controlled study. The trial is not randomized or double-blinded, and it is enrolling approximately 302 adults aged 18 years and older with solid tumors.